Voreloxin
- Product Name
- Voreloxin
- CAS No.
- 175414-77-4
- Chemical Name
- Voreloxin
- Synonyms
- SPC-595;SNS-595;AG-7352;CS-1489;VOSAROXIN;Voreloxin;Voreloxin, >=98%;Voreloxin (SNS-595);Voreloxin USP/EP/BP;SNS-595; VOSAROXIN; AG 7352
- CBNumber
- CB92538816
- Molecular Formula
- C18H19N5O4S
- Formula Weight
- 401.44
- MOL File
- 175414-77-4.mol
Voreloxin Property
- Boiling point:
- 652.0±65.0 °C(Predicted)
- Density
- 1.52±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; insoluble in EtOH; insoluble in DMSO
- form
- solid
- pka
- 5.68±0.70(Predicted)
N-Bromosuccinimide Price
- Product number
- V759000
- Product name
- Voreloxin
- Packaging
- 2.5mg
- Price
- $165
- Updated
- 2021/12/16
- Product number
- V759000
- Product name
- Voreloxin
- Packaging
- 25mg
- Price
- $965
- Updated
- 2021/12/16
- Product number
- orb181346
- Product name
- Voreloxin
- Purity
- >98%
- Packaging
- 100mg
- Price
- $1133.9
- Updated
- 2021/12/16
- Product number
- 42621
- Product name
- Voreloxin
- Packaging
- 25mg
- Price
- $1375
- Updated
- 2021/12/16
- Product number
- orb181346
- Product name
- Voreloxin
- Purity
- >98%
- Packaging
- 250mg
- Price
- $1949.9
- Updated
- 2021/12/16
Voreloxin Chemical Properties,Usage,Production
Uses
Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity.
Biological Activity
voreloxin, formerly known as sns-595 or ag-7352, is a novel naphthyridine analog, which is structurally related to the quinolone antibiotics, a chemical class not previously used for the treatmentof cancer.
in vitro
in vitro studies demonstrated voreloxin has broad anti-proliferative activity in 11 tumor cell lines, with ic50 values ranging from 0.04 to 0.97 μm. similar activity was observed in vitro in drug-resistant cell lines, including those that overexpress p-glycoprotein [2].
in vivo
after a single intravenous dose, voreloxin concentrations in tumor were correlated with induction of the apoptosis marker caspase-3. administration of voreloxin at 20 mg/kg weekly inhibited tumor growth (86%). voreloxin demonstrated strong dose-dependent tumor growth inhibition (63–88%) in 10 of 11 solid tumor xenograft models [2].
References
[1] tsuzuki y, tomita k, shibamori k, sato y, kashimoto s, chiba k. synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. part 2. j med chem. 2004;47(8):2097-109.
[2] hoch u, lynch j, sato y, kashimoto s, kajikawa f, furutani y, silverman ja. voreloxin, formerly sns-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. cancer chemother pharmacol. 2009;64(1):53-65.
[3] advani rh, hurwitz hi, gordon ms, ebbinghaus sw, mendelson ds, wakelee ha, hoch u, silverman ja, havrilla na, berman cj, fox ja, allen rs, adelman dc. voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. clin cancer res. 2010;16(7):2167-75.
Voreloxin Preparation Products And Raw materials
Raw materials
Preparation Products
Voreloxin Suppliers
View Lastest Price from Voreloxin manufacturers
- Product
- Voreloxin 175414-77-4
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-10
- Product
- Voreloxin 175414-77-4
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-08
- Product
- Voreloxin 175414-77-4
- Price
- US $1.00/KG
- Min. Order
- 1G
- Purity
- 98%
- Supply Ability
- 100KG
- Release date
- 2018-08-21